Vertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance

Go back to Vertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance

Vertex Pharma (VRTX) Sees Red-to-Green Reversal Following EPS

April 28, 2016 10:27 AM EDT

Vertex Pharma (NASDAQ: VRTX) reverse sharply off morning lows following earning after the close, which were seen as lackluster.

Shares are currently up 1% after opening down 3.9%.

... More

Vertex (VRTX) PT, Estimates Cut at Baird

April 28, 2016 7:45 AM EDT

Baird analyst Brian Skorney lowered his price target on Vertex (NASDAQ: VRTX) to $128.00 (from $144.00) and Orkambi estimates on weak qua but maintained an Outperform rating.

Skorney commented, "Orkambi sales came in well below expectations that had already been revised significantly downwards over the last... More

Goldman Sachs Downgrades Vertex (VRTX) to Neutral

April 28, 2016 7:16 AM EDT

Goldman Sachs downgraded Vertex (NASDAQ: VRTX) from Buy to Neutral.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $84.50 yesterday.

... More